Keywords: Newron, Meiji Seika, Safinamide, Japan, Asia, Parkinson's disease, Almirall, Daewoong, Aclidinium, COPD, Korea

Newron updates on deal Meiji Seika Pharma deal; Almirall out-licenses in Korea

Article | 14 February 2012

Print This

Italy’s Newron Pharmaceuticals (SIX: NWRN) yesterday said it has finalized a definitive license agreement with Japan’s Meiji Seika ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in